通过结合内啡林-1抗和SGLT-2抑制来向内皮:一起更好?
Phil Ambery1, Peter J Greasley2, Robert I Menzies3
1Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Clinical science (London, England : 1979)
|June 5, 2024
概括
本综述探讨了结合内分泌素受体抗剂和-葡萄糖共运输体-2 (SGLT-2) 抑制剂来治疗涉及内分泌功能障碍的疾病,并建立在各自的成功基础上.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 内分泌素A和B受体和-葡萄糖共运输体-2 (SGLT-2) 通道是增强内分泌体功能的关键标.
- 内甲素受体对抗剂对肺高血压是有效的.
- SGLT-2 抑制剂成功治疗心力衰竭和慢性病.
研究的目的:
- 审查使用向内甲素受体和SGLT-2通道的组合治疗的理由.
- 探索结合这些不同的疾病机制与潜在的内皮功能障碍的潜力.
主要方法:
- 机械学和临床结局试验的文献综述.
- 分析不同的和互补的治疗机制.
- 对各种疾病的组合疗法逻辑的探索.
主要成果:
- 在肺高血压中,内甲素受体对抗剂的确立疗效.
- 在心力衰竭和慢性病中,SGLT-2 抑制剂的已被证明的益处.
- 确定内皮功能障碍作为一种常见的病理途径.
结论:
- 针对内分泌素受体和SGLT-2通道的组合疗法具有前景.
- 这种方法可能为表现为内皮功能障碍的疾病提供协同效益.
- 对联合治疗策略的进一步研究是有必要的.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
617
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
617


